Rethinking Muscle Health Assessment in <scp>GLP</scp> ‐1–Based Therapies for Obesity: Beyond Lean Mass

M.J. reports receiving lecture honoraria from Novo Nordisk, Eli Lilly, Pfeizer, Amgen, AstraZeneca, Novartis and Sanofi and being an advisory board member of Novo Nordisk, Eli Lilly, Amgen and Pfeizer. A.J. has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Abbott, Novo Nordisk, Medtronic, and Sanofi. The data that support the findings of this study are available from the corresponding author upon reasonable request. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70649.